[Event Report] Roundtable on Medical Fee System Measures to Discourage the Spread of AMR (September 28, 2020)
date : 11/5/2020
Tags: AMR
![[Event Report] Roundtable on Medical Fee System Measures to Discourage the Spread of AMR (September 28, 2020)](https://hgpi.org/en/wp-content/uploads/sites/2/AMRalliance-logo-13.jpg)
AMR Alliance Japan (Secretariat: Health and Global Policy Institute (HGPI)) held a Roundtable on Medical Fee System Measures to Discourage the Spread of AMR.
This meeting was held on the basis of AMR Alliance Japan’s overarching policy recommendations published in July 2019 which called for the promotion of measures through the medical fee system to incentivize behaviors that could help to discourage the spread of antimicrobial resistance (AMR).
AMR Alliance Japan members discussed recommendations toward the 2022 revision of the medical fee system. Based on the discussion, AMR Alliance Japan decided on the key items to be targeted in future proposals on the medical fee system revision.
In light of the situation with novel coronavirus, this meeting was carried out primarily online.
■Overview
Date and time: Wednesday, September 28, 2020
Organizer: AMR Alliance Japan (Secretariat: HGPI)
■Program
Roundtable Discussion
・Key items for AMR Alliance Japan’s Medical Fee System Revision Proposal
・Future Plans
■Roundtable Speakers (alphabetical order by last name):
Kazuyuki Akai (Director, Business Development, Nippon Becton Dickinson Company Ltd.)
Midori Hirai (Chair, Pharmaceutical Education Committee, The Pharmaceutical Society of Japan / Director, Japanese Red Cross Hyogo Blood Center)
Masashi Kawata (Senior Manager, Public Affairs & Policy, Corporate Affairs, Health & Value, Pfizer Japan Inc.)
Takashi Kitahara (Chairman, Japan Pharmaceutical Association / Professor, Department of Clinical Pharmacology, Yamaguchi University)
Yuri Miura (Senior Industry Policy Specialist, Public and Industrial Policy, Health Policy, MSD K.K.)
Masaaki Miyakawa (Executive Board Member, Japan Medical Association)
Choichiro Miyazaki (Vice Chairman, Japan Pharmaceutical Association)
Yuichi Muraki (Representative, Japanese Society of Pharmaceutical Health Care and Sciences / Professor, Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University)
Akio Ozaki (Director, Public and Industry Policy, Health Policy, MSD K. K.)
Toshiyuki Sakaeda (President, The Japanese Society of Therapeutic Drug Monitoring / Professor, Department of Pharmacokinetics, Kyoto Pharmaceutical University)
Makoto Seno (Marketing Director, Nippon Becton Dickinson Company Ltd.)
Kazutoshi Shibuya (President, The Japanese Society for Medical Mycology / Professor, Department of Surgical Pathology, Toho University)
Kazuhiro Tateda (President, The Japanese Association for Infectious Diseases / President, The Japanese Society for Clinical Microbiology / Professor, Department of Microbiology and Infectious Diseases, Toho University)
Yasunori Tawaragi (Director, International Affairs, Japan Pharmaceutical Manufacturers Association)
■Moderator:
Yuki Awano (AMR Alliance Japan Secretariat / Associate, HGPI)
Top Research & Recommendations Posts
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
- [Research Report] The 2025 Public Opinion Survey on Healthcare in Japan (March 17, 2025)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Policy Recommendations] Reshaping Japan’s Immunization Policy for Life Course Coverage and Vaccine Equity: Challenges and Prospects for an Era of Prevention and Health Promotion (April 25, 2025)
- [Policy Recommendations] Strengthening Lifelong Mental Health Support for Children with Intellectual Disabilities (April 30, 2025)
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Research Report] 2019 Survey on Healthcare in Japan
- [Policy Recommendations] Achieving a Sustainable Society of Health and Longevity Through the Integration of Environment and Healthcare-Incorporating a Planetary Health Perspective into the 3rd Phase of The Healthcare Policy-(December 20, 2024)
- [Event Report] Round Table Discussion “Understanding Menopausal Women’s Health as a Social Issue” (Preliminary Version) (November 19, 2024)
- [Recommendations] HGPI Expert Policy Advocacy Platform “Better Use of Cost-effectiveness Evaluation for Pharmaceuticals in Japan” (May 7, 2025)
Featured Posts
-
2025-04-17
[Registration Open] (Webinar) The 134th HGPI Seminar “Understanding Evidence-Based Dietary Guidelines: Leveraging the Dietary Reference Intakes for Japanese” (May 28, 2025)
-
2025-04-23
[Registration Open] Recruitment of the Health Policy Academy the 14th Session (Starts July 2025)
-
2025-05-02
[Registration Open] (Webinar) The 133rd HGPI Seminar -HGPI Expert Policy Advocacy Platform- “Better Use of Cost-effectiveness Evaluation for Pharmaceuticals in Japan” (May 20, 2025)
-
2025-05-07
[Recommendations] HGPI Expert Policy Advocacy Platform “Better Use of Cost-effectiveness Evaluation for Pharmaceuticals in Japan” (May 7, 2025)
-
2025-05-07
[Registration Open] Japan-Australia Online Round Table Discussion “The Impact of Social Media on the Mental Health of Children and Young People and How Social Media Should Be Used in Society“ (May 23, 2025)